De­moc­rats urge HHS to 'march-in' or en­able 'gov­ern­ment-use' rights to make Xtan­di less ex­pen­sive

HHS should move for­ward with a re­cent pe­ti­tion to al­low the gov­ern­ment to ex­er­cise its “march-in” rights to low­er the price of Astel­las and Pfiz­er’s can­cer drug Xtan­di, known gener­i­cal­ly as en­za­lu­tamide, Sens. Eliz­a­beth War­ren (D-MA) and An­gus King (I-ME), and Rep. Lloyd Doggett (D-TX) said in a let­ter to HHS Sec­re­tary Xavier Be­cer­ra late last week.

If NIH con­tin­ues to de­cide to nev­er use its march-in rights un­der the Bayh-Dole Act, the De­moc­rats note that the fed­er­al gov­ern­ment can al­so ex­er­cise its gov­ern­ment-use rights to per­mit gener­ic com­pe­ti­tion with Xtan­di.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER